Compounds > sdz wag-994
Page last updated: 2024-12-08

sdz wag-994

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N(6)-cyclohexyl-2-O-methyladenosine: an A1-adenosine receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID164305
CHEMBL ID117904
SCHEMBL ID303794
MeSH IDM0240288

Synonyms (27)

Synonym
sdz wag 994
sdz-wag-994
(2r,3r,4r,5r)-5-(6-cyclohexylamino-purin-9-yl)-2-hydroxymethyl-4-methoxy-tetrahydro-furan-3-ol
bdbm50080396
CHEMBL117904 ,
130714-47-5
n-cyclohexyl-2'-o-methyladenosine
(2r,3r,4r,5r)-5-[6-(cyclohexylamino)purin-9-yl]-2-(hydroxymethyl)-4-methoxyoxolan-3-ol
unii-567ewi9u1e
567ewi9u1e ,
n(6)-cyclohexyl-2-o-methyladenosine
adenosine, n-cyclohexyl-2'-o-methyl-
sdz wag-994
SCHEMBL303794
(2s,3s,4s,5s)-5-(6-(cyclohexylamino)-9h-purin-9-yl)-2-(hydroxymethyl)-4-methoxy-tetrahydrofuran-3-ol
sdzwag994
sdz-wag 994
wag 994
(2r,3r,4r,5r)-5-(6-(cyclohexylamino)-9h-purin-9-yl)-2-(hydroxymethyl)-4-methoxytetrahydrofuran-3-ol
AKOS024457116
DTXSID30926865
n-cyclohexyl-9-(2-o-methylpentofuranosyl)-9h-purin-6-amine
HMS3677O16
HMS3413O16
Q27261385
A848867
E98669

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Patients had access to escape analgesic and if these were taken, the time and dosage were recorded."( The efficacy of a novel adenosine agonist (WAG 994) in postoperative dental pain.
Andrews, C; Frame, J; Hawkesford, JE; Hill, CM; Seymour, RA, 1999)		0.3
" Neuroprotective properties assessed after postischemic dosing in a Mongolian gerbil severe temporary forebrain ischemia paradigm, using hippocampal CA1 damage endpoints, and the efficacy of these agonists in an A(1) functional assay show similarities to some reference adenosine agonists."( N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
Hansen, AJ; Judge, ME; Knutsen, LJ; Lau, J; Petersen, H; Shalmi, M; Sheardown, MJ; Thomsen, C; Weis, JU, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.07600.00011.20929.9700AID32482
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID73904Negative inotropy effect in isolated guinea pig atria. 1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID130702In vivo inhibition of spontaneous locomotor activity of mouse by the compound 30 min after intraperitoneal administration.1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID30350Displacement of [3H]-CGS- 21680 from adenosine A2A receptor of rat striatal tissue1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID53750In vitro inhibition of isoprenaline-stimulated cAMP accumulation in DDT1-MF2 cells (measured by adenosine A1 functional assay)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID75230Reduction in hippocampal cell death by compound administered 30 min after a period of severe forebrain ischemia in the Mongolian gerbil at 0.3 mg/kg dosed 30 min and 120 min post ischemia1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID130698In vivo inhibition of DMCM-induced seizures in mouse by the compound 30 min after intraperitoneal administration1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID32482Displacement of [3H]R-PIA from adenosine A1 receptor of Wistar rat forebrain1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
AID195501Percent reduction in blood pressure in an anesthetized rat 5 min after intravenous administration of 0.1 mg/kg of compound1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's11 (68.75)18.2507
2000's2 (12.50)29.6817
2010's3 (18.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (18.75%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (68.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		1.9910alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
carbamazepine
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.		2.1310dibenzoazepine;
ureas		analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		3.3811monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
metyrapone
Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.		2.5120aromatic ketoneantimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
thymidine
[no description available]		2.0410pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
uridine
[no description available]		2.0410uridinesdrug metabolite;
fundamental metabolite;
human metabolite
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		1.9910cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
bicuculline
Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.		2.1310benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		8153adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
metrifudil
[no description available]		210
phenylisopropyladenosine
[no description available]		210aromatic amine;
benzenes;
hydrocarbyladenosine;
purine nucleoside;
secondary amino compound		adenosine A1 receptor agonist;
neuroprotective agent
bicuculline methiodide
[no description available]		2.1310
n(6)-cyclopentyladenosine
[no description available]		210
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine: A2 adenosine receptor agonist; structure given in first source. CGS-21680 : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and the hydrogen at position 2 on the adenine is replaced by a 4-(2-carboxyethyl)phenethylamino group.		2.420adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent
1,2-dioleoyloxy-3-(trimethylammonium)propane
1,2-dioleoyloxy-3-(trimethylammonium)propane: fluorescent probe for phospholipids; RN & structure given in first source		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Cerebral Ischemia
[description not available]		0210
Blood Pressure, Low
[description not available]		02.420
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		0210
Hypotension
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.		02.420
Drug Refractory Epilepsy
[description not available]		02.1310
Impaired Glucose Tolerance
[description not available]		02.910
Diabetes Mellitus, Adult-Onset
[description not available]		02.910
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.910
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		02.910
Left Ventricular Dysfunction
[description not available]		03.3711
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		03.3711
Alloxan Diabetes
[description not available]		01.9910
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9910
Insulin Sensitivity
[description not available]		02.9110
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.9110
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		01.9910
Blood Pressure, High
[description not available]		01.9910
Fasting Hypoglycemia
HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.		01.9910
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		01.9910
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		01.9910
Hypoglycemia
A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.		01.9910
Auricular Fibrillation
[description not available]		03.3811
Atrial Fibrillation
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.		03.3811
Acute Post-operative Pain
[description not available]		03.3811
Pain, Postoperative
Pain during the period after surgery.		03.3811